Block admission six monthly return
04 October 2023
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of company:
Fusion Antibodies plc
Name of scheme:
Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
Period of return:
From 2 April 2023 to 1 October 2023
Number and class of securities not issued under the scheme at the beginning of the period:
752,083 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
Number of securities issued under the scheme during the period:
Number of options under the scheme that have lapsed during the period:
Options over 458,333 Ordinary Shares
Balance under the scheme of securities not yet issued at the end of the period:
293,750 Ordinary Shares
Number and class of securities originally admitted and the date of admission:
917,083 Ordinary Shares on 27 September 2021
Contact name and telephone number:
Stephen Smyth, Interim CFO via Walbrook PR
+44 (0)20 7933 8780
Fusion Antibodies plc
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Interim Chief Financial Officer
Via Walbrook PR
Allenby Capital Limited
Tel: +44 (0)20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Tel: +44 (0)20 7933 8780 or [email protected]
Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.